Biomarker screen-guided care for preterm birth risk in nulliparous pregnancies: a subgroup analysis of the PRIME randomized controlled trial.

J Matern Fetal Neonatal MedJul 8, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Anthony C Sciscione, Cynthia Gyamfi-Bannerman, Michael Walker et al.

✦ AI-curated · Sources linked

In 30 seconds

This subgroup analysis of the PRIME randomized controlled trial evaluated the effectiveness of biomarker-guided care in nulliparous pregnancies at risk for preterm birth. Among 1783 nulliparous participants, the screen-guided care arm showed a significant reduction in NICU admissions (12.8% vs 16.4%, p = 0.039) compared to routine care, indicating improved neonatal outcomes.

Key findings

  • Screen-guided care reduced composite neonatal morbidity scores in nulliparous pregnancies.
  • NICU admission rate was 12.8% in the screen-guided care arm versus 16.4% in routine care (p = 0.039).
  • The number needed to screen to prevent one NICU admission was 28.
  • Adjusted analysis showed fewer NICU admissions in the screen-guided care arm (OR 0.75; 95% CI, 0.57-0.98; p = 0.036).

Why it matters

These findings highlight the potential of biomarker-guided strategies to improve neonatal outcomes in first-time pregnancies, particularly for those at higher risk of preterm birth, thereby informing clinical decision-making in obstetric care.

Source

PubMed · PMID 42420160

Published in J Matern Fetal Neonatal Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.